Osteoporosis Drug Deal Dies
<i> Bloomberg Business News</i>
NEW YORK —
Pfizer Inc. and Procter & Gamble Co. have scrapped plans to co-develop an osteoporosis drug after failing to agree on final commercial terms.
Last September, the companies agreed to jointly develop Procter & Gamble’s prescription drug, Risedronate, to treat osteoporosis.
The companies said late Tuesday they were unable to reach final commercial terms, but didn’t elaborate.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
